BIO Long Put Strategy
BIO (Bio-Rad Laboratories, Inc.), in the Healthcare sector, (Medical - Devices industry), listed on NYSE.
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market.
BIO (Bio-Rad Laboratories, Inc.) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $6.58B, a trailing P/E of 38.89, a beta of 1.06 versus the broader market, a 52-week range of 211.43-343.12, average daily share volume of 335K, a public-listing history dating back to 1980, approximately 8K full-time employees. These structural characteristics shape how BIO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.06 places BIO roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline. The trailing P/E of 38.89 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple.
What is a long put on BIO?
A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration.
Current BIO snapshot
As of May 15, 2026, spot at $247.19, ATM IV 36.60%, IV rank 2.58%, expected move 10.49%. The long put on BIO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this long put structure on BIO specifically: BIO IV at 36.60% is on the cheap side of its 1-year range, which favors premium-buying structures like a BIO long put, with a market-implied 1-standard-deviation move of approximately 10.49% (roughly $25.94 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated BIO expiries trade a higher absolute premium for lower per-day decay. Position sizing on BIO should anchor to the underlying notional of $247.19 per share and to the trader's directional view on BIO stock.
BIO long put setup
The BIO long put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With BIO near $247.19, the first option leg uses a $250.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed BIO chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 BIO shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Put | $250.00 | $11.85 |
BIO long put risk and reward
- Net Premium / Debit
- -$1,185.00
- Max Profit (per contract)
- $23,814.00
- Max Loss (per contract)
- -$1,185.00
- Breakeven(s)
- $238.15
- Risk / Reward Ratio
- 20.096
Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium.
BIO long put payoff curve
Modeled P&L at expiration across a range of underlying prices for the long put on BIO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$23,814.00 |
| $54.66 | -77.9% | +$18,348.60 |
| $109.32 | -55.8% | +$12,883.21 |
| $163.97 | -33.7% | +$7,417.81 |
| $218.63 | -11.6% | +$1,952.41 |
| $273.28 | +10.6% | -$1,185.00 |
| $327.93 | +32.7% | -$1,185.00 |
| $382.59 | +54.8% | -$1,185.00 |
| $437.24 | +76.9% | -$1,185.00 |
| $491.90 | +99.0% | -$1,185.00 |
When traders use long put on BIO
Long puts on BIO hedge an existing long BIO stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying BIO exposure being hedged.
BIO thesis for this long put
The market-implied 1-standard-deviation range for BIO extends from approximately $221.25 on the downside to $273.13 on the upside. A BIO long put expresses a directional view that the underlying closes below the strike minus premium at expiration, frequently sized to hedge an existing long BIO position with one put per 100 shares held. Current BIO IV rank near 2.58% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on BIO at 36.60%. As a Healthcare name, BIO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to BIO-specific events.
BIO long put positions are structurally bearish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. BIO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move BIO alongside the broader basket even when BIO-specific fundamentals are unchanged. Long-premium structures like a long put on BIO are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current BIO chain quotes before placing a trade.
Frequently asked questions
- What is a long put on BIO?
- A long put on BIO is the long put strategy applied to BIO (stock). The strategy is structurally bearish: A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration. With BIO stock trading near $247.19, the strikes shown on this page are snapped to the nearest listed BIO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are BIO long put max profit and max loss calculated?
- Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium. For the BIO long put priced from the end-of-day chain at a 30-day expiry (ATM IV 36.60%), the computed maximum profit is $23,814.00 per contract and the computed maximum loss is -$1,185.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a BIO long put?
- The breakeven for the BIO long put priced on this page is roughly $238.15 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current BIO market-implied 1-standard-deviation expected move is approximately 10.49%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long put on BIO?
- Long puts on BIO hedge an existing long BIO stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying BIO exposure being hedged.
- How does current BIO implied volatility affect this long put?
- BIO ATM IV is at 36.60% with IV rank near 2.58%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.